Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

product candidates; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; the accuracy of AcelRx Pharmaceuticals' estimates regarding expenses, capital requirements and needs for financing; AcelRx Pharmaceuticals' ability to repay a portion of the principal under the loan and security agreement with Hercules with common stock; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K for the year ended December 31, 2011 and the Quarterly Report on Form 10-Q for the three months ended March 31, 2012.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

 SELECTED FINANCIAL DATA(in thousands, except per share data)(unaudited) Three Months Ended March 31, 20122011Statement of Operations DataResearch grant revenue

$
329$
-Operating expenses:Research and development (1)

4,7711,946General and administrative (1)

2,1041,589Total operating expenses

6,8753,535Loss from operations

(6,546)(3,535)Interest expense

(594)(1,359)Interest income and Other income (expense), net

751,690Net loss

$
(7,065)$
(3,204)Basic and diluted net loss per common share

$
(0.36)$
(0.30)Shares used in computing basic and diluted net loss per common share'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
(Date:10/1/2014)... , Oct. 1, 2014   Cypher Genomics, Inc., ... of J. Patrick Ravenel as chief technology ... software and systems experience and a proven track record ... "Patrick has been recognized as a ... systems and is known industry-wide for delivering innovative products ...
(Date:10/1/2014)... 1, 2014 Quantum Materials Corp (OTCQB:QTMM) ... of photoactive quantum dots for use in ... numerous advantages for solar power generation, the high ... quantum dots with which to develop thin film ... commercial utilization and acceptance. The company is also ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... growing appetite for health and wellness devices, and this represents ... been tapped, according to a study from IBM (NYSE: ... wellness device innovations of the future, which have the potential ... healthcare provider over the next five years. (Photo: ...
... 2011 Providers of durable medical equipment and services (DME) ... repeal Medicare,s controversial "competitive" bidding for homecare, which cuts quality ... The program is opposed by the ... advocacy groups such as the ALS Association and ...
Cached Medicine Technology:IBM Study Identifies New Generation of Connected Health Devices 2IBM Study Identifies New Generation of Connected Health Devices 3IBM Study Identifies New Generation of Connected Health Devices 4IBM Study Identifies New Generation of Connected Health Devices 5At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 2At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 3At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 4
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 ... NoteSwift is the bridge between the EHR and Dragon ... clinical information at the point of care. NoteSwift reduces ... by more than half – and virtually eliminates mouse ... state impedes EHR use according to the June 12, ...
(Date:10/1/2014)... 01, 2014 Nordic Naturals is ... very special cause. The campaign—“Buy One Bottle. Help ... for Veterans, a nonprofit organization that helps rebuild ... shelter dogs that would otherwise face euthanasia. From ... will support monthly donations of Nordic Naturals omega-3s ...
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... hope to detect the disease while it is still ... scientists say they have found small molecules in the ... could have diagnostic implications in the future. , Levels ... suffering from pancreatic cancer, the fourth-leading cancer killer in ...
... harsh skin toxicity associated with a widely used cancer drug, ... Cancer Biology and Therapy by researchers from City of ... (Erbitux) is a monoclonal antibody that binds to and inhibits ... to treat colorectal cancer and head and neck cancer. Although ...
... combined with a defibrillator (CRT-D) implanted had a 34 ... failure when compared to patients receiving only an implanted ... online today in the New England Journal of ... of Cardiology Congress (ESC) in Barcelona, Spain. The overall ...
... is available in French . , ... serious autoimmune disorders which cause muscular inflammation are at ... of Montreal researchers. Dr. Christian A. Pineau and his ... Health Centre (RI-MUHC) have linked muscular inflammation to increased ...
... , , , , ... in grants for four Northwest nonprofits: HealthMatters of Central Oregon ... Northwest Organization of Nurse Executives . The grants all ... increase access to care. , , "At The Regence ...
... , PITTSBURGH, Sept. 1 On Friday, September 18, ... former president of the renowned public relations agency Porter Novelli, former ... native William (Bill) D. Novelli. Enjoy lunch and a presentation ... to accomplish this, and what it means for seniors in the ...
Cached Medicine News:Health News:Blood Test May Spot Pancreatic Cancer Early 2Health News:Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs 2Health News:Stuy in NEJM: New therapy prevents heart failure 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits 2
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Medicine Products: